Compounding & Supply News
Every article we’ve published on Compounding & Supply, newest first — 6 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.
Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance
The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.
FDA Unapproved GLP-1 Drugs Alert: What the Agency Is Warning About
The FDA refreshed its standing alert on unapproved GLP-1 drugs used for weight loss on September 1, 2026, restating why products sourced outside the approved supply chain carry risks the agency cannot vouch for. For anyone tracking a semaglutide or tirzepatide protocol, the practical question is where the product came from and what is actually on the label.
Synthetic Semaglutide Claims Challenged Over Reporting Gaps
A newly indexed letter in Diabetes, Obesity & Metabolism takes aim at the evidence behind synthetic semaglutide used for weight management, arguing that reporting gaps make the clinical claims hard to evaluate. For anyone tracking a compounded or non-brand GLP-1 protocol, the argument is about what you can and cannot infer from a study that says the molecule is the same.
Compounded Tirzepatide Facial Nodules Case Report Draws a Rebuttal
A dermatology case report attributing compounded tirzepatide facial nodules to inflammation has drawn a published rebuttal arguing that infection and biofilm were never ruled out. The exchange is a useful window into how thin the evidence still is when a compounded GLP-1 product and a cosmetic filler are in the same patient.
Retatrutide Grey Market Tested: Australian Study Checks Labels
A research letter in Drug and Alcohol Review reports laboratory analysis of vials sold under the retatrutide name in Australia — a direct look at what circulates in the retatrutide grey market. It lands while the compound itself is still years from any approval decision, with a 4,500-participant liver outcomes trial now recruiting.
Compounded Glutathione Recall Over Elevated Endotoxin Levels
An Austin, Texas compounding pharmacy has pulled specified lots of an injectable antioxidant preparation after its own testing flagged a contaminant that sterility testing does not catch. The compounded glutathione recall reaches the patient level, which means vials already dispensed to individuals are covered.